MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3389/fimmu.2026.1789298

Медицинская библиотека · Frontiers in immunology · 2026

Real-world effectiveness and safety of 200 mg abrocitinib initiation in Chinese adults with moderate-to-severe atopic dermatitis: a retrospective study.

Lu Peilin, Zhong Judan, Tan Na, Chen Aijun, Cai Tao, Chen Jin, Chen Shuang

СтатьяНаблюдательное исследованиеПеревод в очереди

Аннотация

BACKGROUND

Abrocitinib, a Janus kinase (JAK) inhibitor approved for moderate-to-severe atopic dermatitis (AD), has demonstrated efficacy at 100 mg in randomized controlled trials. However, real-world data on 200 mg initiation in Chinese patients remain scarce.

OBJECTIVE

To evaluate the real-world effectiveness and safety of initiating abrocitinib at 200 mg in Chinese adults with moderate-to-severe AD.

METHODS

This retrospective study included 20 patients with moderate-to-severe AD treated with abrocitinib. Patients were stratified into Group A (n=7, initiated at 200 mg, tapered to 100 mg if EASI-75 or ≥4-point PP-NRS reduction was achieved by week 12) and Group B (n=13, initiated at 100 mg, escalated to 200 mg if targets were not met). Primary outcomes included Eczema Area and Severity Index (EASI), Investigator Global Assessment (IGA), Peak Pruritus Numeric Rating Scale (PP-NRS), and Dermatology Life Quality Index (DLQI). Adverse events (AEs) were recorded.

RESULTS

Both groups showed significant reductions in all outcome measures at weeks 4, 12, and 24. Baseline DLQI was significantly higher in Group A (22.0 vs. 18.0, P < 0.001). At week 4, Group A showed superior PP-NRS improvement (P = 0.019). By week 12, Group A achieved significantly higher rates of EASI < 5 (57.14% vs. 0%, P < 0.01) and IGA 0/1 (85.71% vs. 7.69%, P < 0.01). Notably, 50% of patients had failed prior systemic therapies, including 85.7% in Group A, reflecting the refractory nature of the cohort. At week 24, Group A maintained superiority in EASI and PP-NRS (P < 0.05), while EASI-75 response exceeded 90% in both groups. AEs were comparable between groups (71.43% vs. 61.54%), with no serious events.

CONCLUSION

The 200 mg initiation strategy offers rapid and sustained disease control, particularly for patients with high baseline disease activity and severe quality of life impairment. The 100 mg strategy achieves favorable outcomes by week 24 for those with milder burden. These findings support personalized dosing, though larger prospective studies are warranted to confirm results.

Для цитирования: Lu Peilin, Zhong Judan, Tan Na, Chen Aijun, Cai Tao, Chen Jin, Chen Shuang. Real-world effectiveness and safety of 200 mg abrocitinib initiation in Chinese adults with moderate-to-severe atopic dermatitis: a retrospective study.. Frontiers in immunology. 2026. DOI: 10.3389/fimmu.2026.1789298.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.